Radiopharmaceutical developer Peregrine Pharmaceuticals has extended its radiolabeling research and development agreement with Paul Scherrer Institut (PSI) of Villigen, Switzerland. The Tustin, CA-based firm has extended its contract with PSI to include research, development, and pre-clinical testing of Tumor Necrosis Therapy (TNT)-based PET imaging agents. Peregrine has been collaborating with PSI to scale-up the radiolabeling processes for its Cotara and Oncolym monoclonal antibody anti-cancer drugs.
By AuntMinnie.com staff writersMarch 13, 2001
Copyright © 2001 AuntMinnie.com